A. Grigg

T. Hughes, A. Grigg, T. Hughes, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Busulphan and phenytoin.

A. Grigg, J. Shepherd, G. Phillips, 1989, Annals of internal medicine.

domain mutations identify imatinib-treated patients with CML who have BCR-ABL kinase Real-time quantitative PCR analysis can be used as a primary screen to

R. Herrmann, P. Browett, A. Schwarer, 2012 .

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.

R. Herrmann, P. Browett, A. Schwarer, 2004, Blood.

Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre‐transplant FDG‐PET scan following salvage chemotherapy

J. Szer, A. Roberts, H. Prince, 2010, British journal of haematology.

Use of computed tomography abdomen and pelvis for investigation of febrile neutropenia in adult haematology patients

A. Grigg, M. Ashby, H. Y. Lim, 2016, Internal medicine journal.

Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014

J. Szer, C. Tam, S. Fleming, 2014, Internal medicine journal.

Esophageal perforation secondary to angio-invasive Candida glabrata following hemopoietic stem cell transplantation.

J. Vincent, A. Grigg, M. Slavin, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Mycobacterium genavense duodenitis following allogeneic peripheral blood stem cell transplantation

J. Sasadeusz, A. Grigg, M. Finlay, 2009, Transplant infectious disease : an official journal of the Transplantation Society.

More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders.

W. Alexander, D. Hilton, J. Szer, 2006, Blood.

Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood

W. Alexander, J. Szer, A. Roberts, 2006, Pathology.

Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study)

P. Marlton, Greg Brown, D. Bowden, 2017, European journal of haematology.

The oral iron chelator deferasirox inhibits NF‐κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia

N. Mifsud, J. Szer, S. Opat, 2015, British journal of haematology.

Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan.

J. Szer, A. Roberts, S. Durrant, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation

J. Szer, D. Ritchie, A. Grigg, 2018, Bone Marrow Transplantation.

Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group

J. Reynolds, D. Goldstein, D. Joseph, 2011, Leukemia & lymphoma.

Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

J. Connors, L. Specht, P. Zinzani, 2020, Leukemia & lymphoma.

An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial

J. Szer, A. Boyd, T. Hughes, 2015, Leukemia & lymphoma.

BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria

Z. Rudzki, J. Seymour, T. Hughes, 2007, Clinical Cancer Research.

Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.

L. To, D. White, T. Hughes, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

P. Browett, A. Schwarer, I. Gathmann, 2003, Leukemia.

Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.

J. Szer, A. Grigg, C. McNamara, 2003, Clinical and laboratory haematology.

Diagnostic medical radiation exposure in surveillance of aggressive lymphoma: clinical trial design should reflect clinical practice.

E. Hawkes, A. Grigg, G. Chong, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia

R. Herrmann, P. Browett, A. Schwarer, 2004 .

Graft versus T-cell-non-Hodgkin's lymphoma effect.

A. Grigg, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Graft versus Burkitt's Lymphoma Effect after Allogeneic Marrow Transplantation

J. Seymour, J. Seymour, A. Grigg, 2002, Leukemia & lymphoma.

Use of 18F‐fluorodeoxyglucose positron emission tomography to change management and assess response to therapy in post‐transplant extramedullary relapse of acute myeloid leukaemia

A. Grigg, D. Gunawardana, 2010, Internal medicine journal.

Venoocclusive liver disease after bone marrow transplantation: findings at duplex sonography.

J. Herbetko, A. Buckley, A. Grigg, 1992, AJR. American journal of roentgenology.

Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit.

J. Szer, C. Kirkpatrick, J. Seymour, 2016, The Journal of antimicrobial chemotherapy.

A phase III randomized trial of high‐dose CEOP + filgrastim versus standard‐dose CEOP in patients with non‐Hodgkin lymphoma: 10‐year follow‐up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial

P. Marlton, J. Matthews, P. Browett, 2014, American journal of hematology.

Final analysis of the UKLG LY02 trial comparing 6–8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL

K. Maclennan, H. Holte, P. Hoskin, 2010, British journal of haematology.

A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.

I. Davis, J. Cebon, M. Green, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Allogeneic stem cell transplantation as a risk factor for recurrent melanoma

H. Stevens, K. Raj, A. Grigg, 2018, Leukemia & lymphoma.

The perioperative management of anticoagulation

A. Grigg, R. Sridhar, 2000 .

Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy.

J. Snowden, I. Wicks, A. Grigg, 1997, Arthritis and rheumatism.

Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG‐rHuMGDF

C. Begley, J. Rasko, C. O’Malley, 1997, British journal of haematology.

photopheresis for treatment of chronic graft-versus-host disease A multicenter prospective phase 2 randomized study of extracorporeal

L. Bouzas, A. Elmaagacli, R. Knobler, 2013 .

A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease.

L. Bouzas, D. Parenti, A. Elmaagacli, 2008, Blood.

Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice

V. Anttila, K. Sullivan, A. Cuneo, 2021, Human vaccines & immunotherapeutics.

Late‐onset pulmonary arterial hypertension in association with graft‐versus‐host disease after allogeneic stem‐cell transplantation

M. Buchanan, A. Grigg, H. Whitford, 2005, American journal of hematology.

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma

A. Roberts, A. Behren, J. Cebon, 2015, Clinical Cancer Research.

Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning

M. Lasica, C. Stern, A. Grigg, 2016, European journal of haematology.

Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma

S. Gibbs, A. Grigg, C. C. Chua, 2018, Bone Marrow Transplantation.

The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft

L. Churilov, S. Hunt, A. Grigg, 2021, Bone Marrow Transplantation.

Chemotherapy for Primary Central Nervous System Lymphoma

E. Thiel, T. Batchelor, A. Grigg, 2012 .

A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation

J. Szer, A. Roberts, A. Grigg, 2004, Bone Marrow Transplantation.

Antimicrobials post transplant A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation

M. Brown, J. Szer, A. Roberts, 2004 .

The impact of conventional and high-dose therapy for lymphoma on fertility.

A. Grigg, 2004, Clinical lymphoma.

Recommendations for the use of pegylated interferon‐α in the treatment of classical myeloproliferative neoplasms

A. Perkins, S. Lane, K. Burbury, 2019, Internal medicine journal.

An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.

M. S. Lewis, M. Sydes, D. Wright, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Is Upfront Escalated BEACOPP for Advanced Hodgkin Lymphoma Becoming a Distant Memory?

E. Hawkes, A. Grigg, G. Chong, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission

M. Gilbertson, E. Hawkes, A. Grigg, 2018, British Journal of Cancer.

Natural killer cell lymphoproliferative disease associated with combined peripheral and autonomic neuropathy

L. Kiers, A. Grigg, R. Boer, 1999, Journal of Clinical Neuroscience.

FATAL THROMBOTIC EVENTS DURING TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA WITH INTRAVENOUS IMMUNOGLOBULIN IN ELDERLY PATIENTS

A. Grigg, F. Firkin, R. Woodruff, 1986, The Lancet.

Fanconi anemia in 55‐year‐old identical twins first presenting as fatal post‐chemotherapy pancytopenia

H. Stevens, M. Wallis, A. Grigg, 2016, American journal of hematology.

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.

A. Ashraf, S. Fleming, A. Schwarer, 2017, Blood advances.

Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation.

C. Mullighan, J. Szer, S. Heatley, 2002, Blood.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

J. Melo, A. Schwarer, J. Seymour, 2013, Blood.

Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation

M. Horowitz, D. Parenti, F. Foss, 2010, Bone Marrow Transplantation.

Long‐term outcome of autoimmune disease following allogeneic bone marrow transplantation

P. Brooks, J. Snowden, J. Biggs, 1998 .

Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease.

H. Karunajeewa, A. Grigg, J. Metz, 1998, Australian and New Zealand journal of medicine.

with for

Christopher, C. Tam, A. Schwarer, 2014 .

BCR-ABL Levels Continue To Decrease up to 42 Months after Commencement of Standard Dose Imatinib in Patients with Newly Diagnosed Chronic Phase CML Who Achieve a Major Molecular Response.

P. Browett, A. Schwarer, Z. Rudzki, 2004 .

Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.

S. Kirsa, R. Nation, D. Al-Badriyeh, 2013, The Journal of antimicrobial chemotherapy.

Phase II study of autologous stem cell transplant using busulfan–melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma

H. Prince, A. Schwarer, D. Gill, 2010, Leukemia & lymphoma.

Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma

P. Hoskin, P. Solal-Céligny, A. Grigg, 2003, Leukemia & lymphoma.

Primary adrenal lymphoma.

J. Connors, A. Grigg, 2003, Clinical lymphoma.

Delayed‐onset neutropenia associated with rituximab therapy

A. Grigg, F. Firkin, R. Filshie, 2003, British journal of haematology.

The diagnosis of idiopathic thrombocytopenic purpura in adults: does bone marrow biopsy have a place?

A. Grigg, D. Westerman, D. Westerman, 1999, The Medical journal of Australia.

A ≥1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse

P. Marlton, D. Gill, J. Seymour, 2008, Leukemia & lymphoma.

A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.

J. Szer, L. To, A. Roberts, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

N. Potter, N. Russell, A. Wei, 2020, British journal of haematology.

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

A. Schwarer, J. Seymour, D. White, 2018, Leukemia.

Running head: Imatinib Cessation After Stable UMRD in CML

J. Melo, A. Schwarer, J. Seymour, 2017 .

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

J. Melo, A. Schwarer, J. Seymour, 2010, Leukemia.

An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study Ann Oncol 2002; 13: 1264–1274

M. S. Lewis, M. Sydes, D. Wright, 2002 .

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

A. Wei, O. Gervásio, S. Avery, 2011 .

Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.

J. Connors, L. Specht, P. Zinzani, 2018 .

Special Issues in Pregnancy

A. Grigg, 2008 .

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia

J. Reynolds, L. Chong, P. Browett, 2012, Haematologica.

High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission

P. Browett, F. Alvaro, A. Grigg, 2020, Bone Marrow Transplantation.

Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals

A. Wei, S. Ting, A. Schwarer, 2019, Leukemia & lymphoma.

Routine Blood Tests in Asymptomatic Patients With Indolent Lymphoma Have Limited Ability to Detect Clinically Significant Disease Progression.

E. Hawkes, A. Grigg, G. Chong, 2020, JCO oncology practice.

Real-world tolerability of venetoclax-based maintenance therapy with azole antifungal prophylaxis for acute myeloid leukemia in remission.

I. Tiong, A. Grigg, Phillip C Nguyen, 2022, Leukemia research.

Cyclosporin a for the Treatment of Pure Red Cell Aplasia Associated with Myelodysplasia

A. Grigg, E. O'Flaherty, E. O'flaherty, 2001, Leukemia & lymphoma.

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.

L. Campbell, J. Szer, I. Lewis, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation.

C. Begley, J. Rasko, C. Begley, 1996, Blood.

The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms

R. Lea, M. Gandhi, P. Marlton, 2012, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Higher-Dose Imatinib (600 mg/Day) with Selective Intensification in Newly Diagnosed CML Patients in Chronic Phase; Cytogenetic Response Rates at 12 Months Are Superior to IRIS.

J. Reynolds, A. Schwarer, Z. Rudzki, 2004 .

Resolution of platelet function defects with imatinib therapy in a patient with chronic myeloid leukaemia in chronic phase.

Ashley P Ng, A. Friedhuber, A. Grigg, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

J. Reynolds, A. Schwarer, J. Seymour, 2005 .

A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 ‘START-A’ Study.

J. Cortes, F. Guilhot, N. Shah, 2005 .

Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response.

A. Schwarer, Z. Rudzki, J. Seymour, 2008 .

Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response

D. Jackson, A. Schwarer, K. Burbury, 2019, Thrombosis and Haemostasis.

Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea

C. Harrison, D. Ritchie, W. Stevenson, 2017, Leukemia & lymphoma.

Prospects for stem cell transplantation in multiple sclerosis

T. Kilpatrick, H. Butzkueven, A. Grigg, 2002, Journal of Clinical Neuroscience.

Echocardiography has low utility in cancer patients with Staphylococcus aureus bacteraemia: findings from a retrospective study

E. Hawkes, A. Grigg, N. Holmes, 2018, Supportive Care in Cancer.

Fatal Anerobic Bacteremia after Hematopoietic Stem Cell Transplant

A. Schwarer, A. Grigg, M. Slavin, 2004, Leukemia & lymphoma.

Spontaneous remission of multilobated non‐Hodgkin lymphoma

A. Grigg, J. Shepherd, G. Gray, 1992, American journal of hematology.

Spontaneous regression of chemotherapy-refractory non-Hodgkin's lymphoma preceding the development of secondary leukaemia.

R. Gascoyne, A. Grigg, M. Barnett, 1996, Leukemia & lymphoma.

Bartonella (Rochalimea) Quintana Causing Fever And Bacteremia In An Immunocompromised Patient With Non‐Hodgkin'S Lymphoma

A. Grigg, A. Grigg, D. Odorico, 1996, Pathology.

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

J. Reynolds, A. Schwarer, J. Seymour, 2008 .

The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adults

A. Grigg, A. Kalff, C. Dowsing, 2010, British journal of haematology.

The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state.

D. Jackson, N. Alhawiti, C. O’Malley, 2016, Thrombosis research.

Autografting followed by rituximab for chemosensitive mantle cell lymphoma: A pilot study and literature review

P. Marlton, J. Seymour, D. Gill, 2005, Leukemia & lymphoma.

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four

M. Gandhi, I. Lewis, R. Hicks, 2015 .

COMPOUND HETEROZYGOSITY FOR HAEMOCHROMATOSIS GENE MUTATIONS AND HEPATIC IRON OVERLOAD IN ALLOGENEIC BONE MARROW TRANSPLANT RECIPIENTS

P. Bhathal, A. Grigg, 2001, Pathology.

Infective Mesenteric Adenitis Masquerading as Relapsed Non-Hodgkin's Lymphoma

A. Grigg, A. Landgren, 2004, Leukemia & lymphoma.

Case Report: Confirmation by Metagenomic Sequencing of Visceral Leishmaniasis in an Immunosuppressed Returned Traveler.

T. Kilpatrick, J. Kwong, T. Seemann, 2020, The American journal of tropical medicine and hygiene.

Thrombotic thrombocytopenic purpura is associated with a high relapse rate after plasma exchange: a single‐centre experience

Ashley P Ng, K. Nicholls, N. Frawley, 2009, Internal medicine journal.

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

J. Connors, K. Savage, Y. Oki, 2018, Blood.

Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.

A. LaCasce, K. Savage, P. Zinzani, 2018, Journal of Clinical Oncology.

Daclizumab in anaplastic large cell lymphoma

A. Grigg, 2006, Leukemia and Lymphoma.

Surgical management of invasive pulmonary fungal infection in hematology patients.

R. Wynne, A. Grigg, M. Slavin, 2009, The Annals of thoracic surgery.

Is there a role for proton pump inhibitor prophylaxis in haematology patients?

A. Grigg, Lisa Hui, E. Leitinger, 2019, Internal medicine journal.

Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.

C. Tam, J. Seymour, D. Ritchie, 2005, Haematologica.

Successful resolution of severe graft versus host disease after liver transplantation correlating with disappearance of donor DNA from the peripheral blood.

A. Grigg, B. Tait, P. Angus, 1998, Australian and New Zealand journal of medicine.

Intermittent granulocyte colony‐stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia

P. Ho, A. Grigg, P. Sherman, 2012, European journal of haematology.

Intermittent G-CSF to maintain dose intensity of chemotherapy for Hodgkin's disease.

A. Grigg, K. Clarke, 1995, Leukemia & lymphoma.

Multiple cycles of aggressive chemotherapy prior to autologous peripheral stem cell transplantation for lymphoma.

J. Szer, A. Grigg, R. Basser, 1997, Australian and New Zealand journal of medicine.

myeloma reveals an adverse prognostic impact of advanced age A multi-centre phase-II trial of thalidomide in relapsed/refractory multiple

J. Biagi, J. Zeldis, J. Seymour, 2013 .

Article Title: A multi-centre phase-II trial of thalidomide in relapsed/refractory multiple myeloma reveals an adverse prognostic impact of advanced age Short Title: Thalidomide/interferon & myeloma

Mbbs, L. Mileshkin, J. Biagi, 2003 .

Recurrent Pseudallescheria boydii sinusitis in acute leukemia.

P. Phillips, A. Grigg, J. Shepherd, 1993, Scandinavian journal of infectious diseases.

Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation

H. Prince, C. McCormack, G. Ryan, 2004, Bone Marrow Transplantation.

Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy

A. Grigg, M. Slavin, 2008, Transplant infectious disease : an official journal of the Transplantation Society.

A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.

J. Zalcberg, I. Davis, J. Cebon, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Staged autologous peripheral blood progenitor cell transplantation for Ewing sarcoma and rhabdomyosarcoma

J. Szer, M. Rosenthal, D. Ritchie, 2004, Internal medicine journal (Print).

Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies

S. Harrison, K. Thursky, A. Grigg, 2015, Haematologica.

Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected] [published erratum appears in Blood 1992 Jun 15;79(12):3397]

D. Reece, A. Eaves, H. Klingemann, 1991 .

Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected].

D. Reece, A. Eaves, M. Barnett, 1991, Blood.

Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT.

J. Szer, W. Sheridan, A. Grigg, 1993, Bone marrow transplantation.

2'-Deoxycoformycin for hepatosplenic gammadelta T-cell lymphoma.

A. Grigg, 2001, Leukemia & lymphoma.

Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation

J. Szer, A. Grigg, P. Ebeling, 2006, Internal medicine journal.

Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia

R. Herrmann, J. Szer, J. Matthews, 1999, British journal of haematology.

Mobilization of predominantly Philadelphia chromosome‐negative blood progenitors using cyclophosphamide and rHUG‐CSF in early chronic‐phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control

R. Herrmann, J. Szer, A. Schwarer, 1997, British journal of haematology.

Breakthrough Disseminated Scedosporium prolificans Infection in a Patient with Relapsed Leukaemia on Prolonged Voriconazole Followed by Posaconazole Prophylaxis

A. Grigg, M. Slavin, M. Ananda-Rajah, 2008, Mycopathologia.

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes.

M. Gandhi, R. Trappe, J. Nourse, 2011, American journal of blood research.

Original Article Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 + T-cell epitopes

Michael R. Green, M. Gandhi, R. Trappe, 2011 .

Abbreviated dose rituximab for immune‐mediated hematological disorders

H. Fairweather, A. Grigg, A. Tuckfield, 2008, American journal of hematology.

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

J. D. van der Walt, P. Campbell, A. Green, 2005, The New England journal of medicine.

Making sense of posaconazole therapeutic drug monitoring: a practical approach

A. Grigg, M. Slavin, M. Ananda-Rajah, 2012, Current opinion in infectious diseases.

Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections

T. Sorrell, J. Szer, A. Roberts, 2004, Internal medicine journal.

Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.

D. Liew, D. Al-Badriyeh, K. Thursky, 2010, The Journal of antimicrobial chemotherapy.

Prophylaxis and treatment of patients with aspergillosis: an overview, including the Royal Melbourne Hospital experience.

A. Grigg, 2002, The Journal of antimicrobial chemotherapy.

Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period

Tim Spelman, Allen Cheng, A. Cheng, 2012, Haematologica.

Substantial variation in post‐engraftment infection prophylaxis and revaccination practice in autologous stem cell transplant patients

A. Grigg, H. Y. Lim, H. Y. Lim, 2016, Internal medicine journal.

Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease

A. Grigg, 2007, Internal medicine journal.

Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study.

D. Parenti, A. Elmaagacli, K. van Besien, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.

A. Peleg, J. Seymour, D. Ritchie, 2016, The Journal of antimicrobial chemotherapy.

Hepatitis B reactivation after thalidomide

J. Sasadeusz, A. Grigg, A. Grigg, 2008, Internal medicine journal.

Prophylaxis of cytomegalovirus disease in allogeneic bone marrow transplantation.

G. Phillips, A. Grigg, 1992, The Journal of infectious diseases.

The effect of folinic acid on methylenetetrahydrofolate reductase polymorphisms in methotrexate-treated allogeneic hematopoietic stem cell transplants.

J. McCluskey, J. Szer, R. Holdsworth, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CsA 2-h concentration correlates best with area under the concentration–time curve after allo-SCT compared with trough CsA

A. Grigg, P. Shuttleworth, D. C. Kong, 2012, Bone Marrow Transplantation.

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

R Smith, F. Aversa, W. Brugger, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

Nicola D. Roberts, J. Seymour, T. Hughes, 2014, Blood.

The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients

S. Harrison, D. Ritchie, A. Grigg, 2018, Annals of Hematology.

New advances in the management of cytomegalovirus in allogeneic haemopoietic stem cell transplantation

J. Kok, D. Ritchie, W. Rawlinson, 2020, Internal medicine journal.

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

R. Herrmann, Z. Rudzki, T. Hughes, 2002, Blood.

Cladribine followed by autologous stem‐cell transplantation in progressive multiple sclerosis

H. Butzkueven, N. Tubridy, J. Szer, 2004, Internal medicine journal.

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

Susan Branford, Richard Herrmann, R. Herrmann, 2003, Blood.

Genomics analysis of leukaemia predisposition in X‐linked agammaglobulinaemia

O. Ohara, M. V. van Zelm, H. Kanegane, 2021, British journal of haematology.

Functional Antibody Responses Following Allogeneic Stem Cell Transplantation for TP53 Mutant pre-B-ALL in a Patient With X-Linked Agammaglobulinemia

M. V. van Zelm, Joanne M. Smart, A. Grigg, 2019, Front. Immunol..

Chemotherapy and granulocyte colony stimulating factor‐mobilized blood cell infusion followed by interferon‐α for relapsed malignancy after allogeneic bone marrow transplantation

J. Szer, A. Schwarer, A. Grigg, 2001, Internal medicine journal.

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.

M. Shipp, A. Ligon, S. Ansell, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

A. B. Lyons, L. To, D. White, 2005, Blood.

Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation.

P. Brooks, J. Snowden, J. Biggs, 1998, Arthritis and rheumatism.

Programmed cell death-1 inhibition in lymphoma.

E. Hawkes, A. Grigg, G. Chong, 2015, The Lancet. Oncology.

Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era

A. Schwarer, E. Hawkes, A. Grigg, 2016, Annals of Hematology.

Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration

A. Grigg, A. Grigg, S. He, 2014, Internal medicine journal.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Francisco Cervantes, Ryuzo Ohno, Richard E. Clark, 2013, Blood.

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

L. Mileshkin, J. Biagi, J. Zeldis, 2003, Blood.

RESPONSE OF CML TO MEK INHIBITION 1-1-Cellular mechanisms underlying complete hematological response of chronic myeloid leukemia to BRAF and MEK 1 / 2 inhibition in a patient with concomitant metastatic melanoma

A. Roberts, A. Behren, J. Cebon, 2015 .

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.

Deborah L White, Simon Durrant, Susan Branford, 2008, Blood.

Graft-versus-lymphoma effect in progressive hepatosplenic gamma/delta T-cell lymphoma

A. Roberts, D. Ritchie, A. Grigg, 2007, Leukemia & lymphoma.

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.

C. Tam, A. Schwarer, D. White, 2015, Blood.

Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia.

A. Grigg, Andrew Wei, Andrew Grigg, 2001, Blood.

Pancytopenia due to hypersplenism after allogeneic bone marrow transplantation.

K. Berean, A. Grigg, G. Phillips, 1992, Bone marrow transplantation.

Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.

J. Szer, A. Roberts, G. Hill, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation

C. Mullighan, J. Szer, S. Heatley, 2004, Transplantation.

Bi-Allelic Mutations in STXBP2 Reveal a Complementary Role for STXBP1 in Cytotoxic Lymphocyte Killing

N. Brown, J. Trapani, I. Voskoboinik, 2018, Front. Immunol..

Dilemmas in the diagnosis and pathogenesis of atypical late‐onset familial haemophagocytic lymphohistiocytosis

I. Voskoboinik, A. Grigg, Adrian Minson, 2021, Clinical & translational immunology.

Management of Patients With Erythropoietic Protoporphyria–Related Progressive Liver Disease

P. Angus, P. Gow, A. Testro, 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Gram-negative organisms predominate in Hickman line-related infections in non-neutropenic patients with hematological malignancies.

J. Sasadeusz, A. Grigg, L. Chee, 2008, The Journal of infection.

Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features

A. Morley, J. Seymour, A. Grigg, 2011, Haematologica.

Correlation of T-cell immune response with spontaneous resolution and subsequent relapse of Hodgkin's lymphoma

M. Gandhi, A. Grigg, U. Dua, 2006, Leukemia & lymphoma.

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.

L. Campbell, J. Reynolds, J. Szer, 2015, The Lancet. Haematology.

Durable resolution of recurrent microvascular small bowel ischaemia and severe abdominal pain by eculizumab in paroxysmal nocturnal haemoglobinuria

J. Szer, A. Grigg, M. Brown, 2010, Internal medicine journal.

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.

K. Sullivan, G. Gaidano, L. Cámpora, 2019, JAMA.

Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission

M. Gilbertson, E. Hawkes, A. Grigg, 2018, British Journal of Cancer.

Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure after frontline immunochemotherapy

W. Hiddemann, R. Marcus, M. Herold, 2020, American journal of hematology.

Cerebral toxoplasmosis in a patient with prolonged CD4 lymphopenia post autologous hemopoietic stem cell transplant

A. Grigg, Arielle van Mourik, 2019, Leukemia & lymphoma.

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

J. Raemaekers, M. Pfreundschuh, H. Tilly, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor.

J. Bashford, A. Grigg, P. Mollee, 1999, Leukemia research.

Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate

J. McCluskey, J. Szer, B. King, 2006, Bone Marrow Transplantation.

Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology.

D. Ritchie, A. Grigg, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prolonged Disease-Free Survival after Autografting for Chemosensitive Non-Bulky Low Grade Non-Hodgkin's Lymphoma

J. Szer, A. Grigg, A. Grigg, 2000, Leukemia & lymphoma.

Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.

J. Zalcberg, M. Green, R. Fox, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Viability and quantification of progenitor cells in venesected blood from patients receiving escalated-dose epirubicin and cyclophosphamide with G-CSF for lymphoma: potential role in further increasing dose-intensity.

J. Cebon, A. Grigg, E. O'Flaherty, 1997, Leukemia & lymphoma.

Nivolumab induces dynamic alterations in CD8 T-cell function and TIM-3 expression when used to treat relapsed acute myeloid leukemia after allogeneic stem cell transplantation

J. Szer, A. Grigg, R. Koldej, 2020, Leukemia & lymphoma.

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

A. Roberts, S. Opat, C. Tam, 2015 .

Hydroxyurea-induced fever and hepatitis.

A. Schwarer, A. Grigg, D. Westerman, 1998, Australian and New Zealand Journal of Medicine.

Hyperviscosity Syndrome In Disseminated Breast Adenocarcinoma

D. Horsfall, J. Allardice, A. Grigg, 1994, Pathology.

Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea

A. Grigg, C. Forsyth, E. Verner, 2014, Leukemia & lymphoma.

Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI.

E. Hawkes, A. Grigg, G. Chong, 2018, Blood reviews.

Association of acute inflammatory demyelinating polyneuropathy with acute lymphoblastic leukaemia and HLA-A11

S. Davis, L. Kiers, A. Grigg, 1998, Journal of Clinical Neuroscience.

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

P. Marlton, A. Roberts, A. Wei, 2020 .

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

P. Marlton, A. Roberts, A. Wei, 2020, Blood.

Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission.

J. Szer, M. Tallman, J. Rowe, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cisplatin, fludarabine, and cytarabine

J. Szer, J. Seymour, R. Fox, 2002, Cancer.

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment

D. White, T. Hughes, A. Grigg, 2017, Leukemia.

Ethanol versus heparin locks for the prevention of central venous catheter-associated bloodstream infections: a randomized trial in adult haematology patients with Hickman devices.

J. Szer, A. Grigg, M. Slavin, 2014, The Journal of hospital infection.

A Randomized Single−Blind Study of Extracorporeal Photopheresis with UVADEX® Plus Conventional Therapy (CT) Compared to CT Alone in Chronic GVHD.

L. Bouzas, A. Elmaagacli, H. Greinix, 2006 .

Optimal regimens for the mobilization and collection of peripheral blood progenitor cells from normal donors.

A. Roberts, A. Grigg, 1997, Leukemia & lymphoma.

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).

J. Reynolds, J. Szer, C. Tiley, 2012, Blood.

Multiply recurrent extramedullary plasmacytomas without marrow relapse in the context of extensive chronic GVHD in a patient with myeloma.

A. Grigg, 1999, Leukemia & lymphoma.

Central nervous system multiple myeloma – potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains

P. Ho, D. Ritchie, A. Grigg, 2013, British journal of haematology.

Phase II study of glycosylated recombinant human granulocyte colony-stimulating factor after HLA-identical sibling bone marrow transplantation.

A. Roberts, A. Grigg, J. Lickliter, 1994, Australian and New Zealand journal of medicine.

following allogeneic hemopoietic stem cell transplantation Mannose-binding lectin gene polymorphisms are associated with major

C. Mullighan, J. Szer, S. Heatley, 2002 .

Treatment With Recombinant Interferon (a-2P) Early After Bone Marrow Transplantation in Patients at High Risk for Relapse

D. Reece, A. Eaves, A. Grigg, 1991 .

High Dose Cytarabine (HiDAC) and Fludarabine Without Anthracycline For Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): The Australasian Leukaemia and Lymphoma Group (ALLG) AMLM13 Study

I. Lewis, P. Marlton, D. Zannino, 2013 .

An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial

P. Ganly, P. Ebeling, A. D’Souza, 2017, Bone Marrow Transplantation.

Mechanisms of Bone Loss Following Allogeneic and Autologous Hemopoietic Stem Cell Transplantation

J. Hopper, J. Szer, P. Ebeling, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

New approaches to the management of poor prognosis non-seminomatous germ cell tumours.

A. Grigg, R. Fox, J. McKendrick, 1992, Australian and New Zealand journal of medicine.

Do steady-state peripheral blood progenitor cell (PBPC) counts predict the yield of PBPC mobilized by filgrastim alone?

C. Begley, A. Roberts, A. Grigg, 1995, Blood.

Impact of palifermin on mucosal toxicity in autologous stem cell transplants using busulfan–melphalan conditioning chemotherapy for Hodgkin and non-Hodgkin lymphoma

A. Grigg, A. Bajel, P. Campbell, 2012, Leukemia & lymphoma.

High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity.

M. Rosenthal, W. Sheridan, A. Grigg, 1994, Leukemia & lymphoma.

Long-term interferon-alpha 2A does not induce sustained hematologic remission in younger patients with essential thrombocythemia.

H. Kronenberg, A. Grigg, T. Olsen, 1999, Leukemia & lymphoma.

Portal or hepatic vein thrombosis as the first presentation of a myeloproliferative disorder in patients with normal peripheral blood counts.

A. Grigg, S. Juneja, M. Wolf, 2002, Clinical and laboratory haematology.

A multicenter phase 2 study of risk‐adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma

J. Catalano, A. Grigg, C. Arthur, 2008, Cancer.

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

M. Gandhi, C. Cheah, E. Hawkes, 2020, British journal of haematology.

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

M. Gandhi, I. Lewis, R. Hicks, 2017, Haematologica.

Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B‐cell lymphoma receiving rituximab‐chemotherapy combinations

C. Cheah, E. Hawkes, A. Grigg, 2019, British journal of haematology.

Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre

S. Opat, C. Tam, M. Gilbertson, 2022, Internal medicine journal.

A multi‐centre, single‐arm, open‐label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R‐ITP1000 study)

M. Gandhi, P. Marlton, J. Catalano, 2014, British journal of haematology.

Deep venous thrombosis as the presenting feature in a patient with coeliac disease and homocysteinaemia.

A. Grigg, 1999, Australian and New Zealand journal of medicine.

The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia

A. Schwarer, Simon Wu, I. Tiong, 2021, Leukemia & lymphoma.

Haemolytic uraemic syndrome and prostatic cancer.

V. Perkovic, G. Becker, A. Grigg, 1999, Australian and New Zealand journal of medicine.

Demonstration of monoclonal IgE by isoelectric focusing: first reported case of IgE myeloma in Australia.

R. McLachlan, R. A. Harris, A. Grigg, 1988, Clinical chemistry.

All-trans-retinoic acid , idarubicin , and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia ( APML 4 )

J. Reynolds, J. Szer, C. Tiley, 2012 .

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

A. Schwarer, D. White, T. Hughes, 2010 .

Two Year Data from a Prospective Safety Study Analyzing the Consequences of Imatinib Mesylate Inhibition of Sensitive Kinases Other Than bcr-abl in Patients with Previously Untreated Chronic Phase CML.

J. Reynolds, A. Schwarer, J. Seymour, 2006 .

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

A. Schwarer, D. White, T. Hughes, 2011 .

The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia

C. Tam, M. Lasica, J. Butler, 2019, Leukemia & lymphoma.

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

A. Schwarer, D. White, T. Hughes, 2012 .

Low dose PD‐1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD

A. Grigg, Adrian Minson, I. Bilmon, 2019, British journal of haematology.

An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma

S. Berlangieri, E. Hawkes, A. Grigg, 2018, Leukemia & lymphoma.

Successful Transplant Outcome in a Morbidly Obese Patient with Acute Myeloblastic Leukemia

A. Grigg, A. Wirth, D. Ritchie, 2001, Leukemia & lymphoma.

Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts

C. Tam, A. Tedeschi, W. Wierda, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Methotrexate Therapy for Psoriasis

D. Hare, A. Grigg, 1988 .

therapy in acute promyelocytic leukemia (APML4) -retinoic acid, idarubicin, and IV arsenic trioxide as initial trans All-

J. Reynolds, J. Szer, C. Tiley, 2013 .

Cerebral Hodgkin lymphoma causing leptomeningeal foam cell vasculopathy with cerebral infarction

A. Grigg, L. Galea, A. Arumugaswamy, 2013, Leukemia & lymphoma.

Management of Pregnancy in Women With Chronic Myeloid Leukemia.

J. Seymour, T. Hughes, K. Burbury, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Limited utility of routine chest X‐ray in initial evaluation of neutropenic fever in patients with haematological diseases undergoing chemotherapy

L. Churilov, E. Hawkes, A. Grigg, 2018, Internal medicine journal.

The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.

A. Ashraf, S. Fleming, A. Schwarer, 2019, Blood advances.

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

A. Scott, L. Churilov, T. Witkowski, 2019, Blood.

Mentoring in the management of hematological malignancies

J. Szer, C. Steer, D. Stella, 2010, Asia-Pacific journal of clinical oncology.

Mentoring in the management of hematological

J. Szer, C. Steer, D. Stella, 2010 .

Severe intravascular hemolysis associated with interferon treatment for chronic myeloid leukemia

A. Grigg, J. Metz, Annabel Tuckfield, 1996, American journal of hematology/oncology.

Intramedullary spinal cord sarcoidosis presenting with urinary retention.

S. Davis, M. Rosenthal, A. Grigg, 1992, Australian and New Zealand journal of medicine.

Bleeding due to an acquired inhibitor of platelet associated factor V.

A. Grigg, R. Dauer, P. Thurlow, 1989, Australian and New Zealand journal of medicine.

Early radiological intervention and haematology screening is associated with excellent outcomes in Budd–Chiari syndrome

P. Angus, A. Testro, A. Grigg, 2017, Internal medicine journal.

Reply: Letters to the Editor

J. Szer, A. Grigg, M. Slavin, 2004 .

Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy

R. M. Fox, C. Begley, J. Szer, 1992, The Lancet.

Differential effects of tyrosine kinase inhibitors in haemostasis, thrombosis and inflammation

A. Schwarer, N. Alhawiti, C. O’Malley, 2018 .

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

R. D'Andrea, A. Wei, A. Dear, 2014, Blood Cancer Journal.

AVELUMAB MONOTHERAPY FOLLOWED BY A PET ADAPTED CHEMOTHERAPY APPROACH IN THE FIRST LINE TREATMENT OF CLASSICAL HODGKIN LYMPHOMA: INITIAL RESULTS FROM THE AVENUE WINDOW STUDY

C. Burton, K. Peggs, S. Barrington, 2023, Hematological Oncology.

Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation

L. Mileshkin, J. Biagi, H. Prince, 2001, Bone Marrow Transplantation.

Approaches to the treatment of Philadelphia-positive acute lymphoblastic leukemia.

A. Grigg, 1993, Bone Marrow Transplantation.

Nivolumab for Relapsed or Residual Haematological Malignancies after Allogeneic Haematopoietic Stem Cell Transplantation (NIVALLO)

J. Szer, M. Ludford-Menting, D. Ritchie, 2018, Blood.

Passive donor‐to‐recipient transfer of antiphospholipid syndrome following allogeneic stem‐cell transplantation

D. Ritchie, A. D’Souza, A. Grigg, 2005, American journal of hematology.

Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

A. Scott, Charmaine D. Smith, L. Churilov, 2020 .

Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention

Paul P. S. Wang, D. Thomson, H. Scott, 2023, Haematologica.

Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse

J. Storek, A. Grigg, J. Russell, 2013, Bone Marrow Transplantation.

Increasing Frequency and Marked Stability of Complete Molecular Response Is Observed in Imatinib-Treated CML Patients with Long-Term Follow Up.

J. Seymour, S. Branford, A. Grigg, 2006 .

Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir

J. Szer, J. Matthews, J. Sasadeusz, 2000, Bone Marrow Transplantation.

An Unusual Case of Bardet–Biedl Syndrome Presenting with Pancytopenia

R. Dowling, A. Grigg, D. Zantomio, 2006 .

Urine cultures at the onset of febrile neutropenia rarely impact antibiotic management in asymptomatic adult cancer patients

E. Hawkes, A. Grigg, S. Grigg, 2018, Supportive Care in Cancer.

Early radiological intervention and haematology screening is associated with excellent outcomes in Budd–Chiari syndrome

P. Angus, A. Testro, A. Grigg, 2017, Internal medicine journal.

Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study.

D. Parenti, A. Elmaagacli, K. van Besien, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The oral iron chelator deferasirox inhibits NF‐κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia

N. Mifsud, J. Szer, C. Tam, 2015, British journal of haematology.

An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial

J. Szer, A. Boyd, S. Durrant, 2015, Leukemia & lymphoma.

Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era.

A. Grigg, T. Hughes, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Optimal oral cyclosporin dosing with concomitant posaconazole post allogeneic stem cell transplantation

Charlotte F M Hughes, A. Grigg, Danielle H Robinson, 2020, Leukemia & lymphoma.

P. Marlton, J. Matthews, P. Browett, 2014, American journal of hematology.